In Pfizer’s first-quarter 2017 financial report, total revenue was down 2 percent year over year. The company also reported three discontinued pipeline projects.
Pharmaceutical company AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer Inc. in a deal that could be valued at more than $1.5 billion.
New timelines were announced for a U.S. FDA decision on Iglarlixi, the fixed-ratio combination of Adlyxin (lixisenatide) and Lantus, for treating type 2 diabetes.
January 28, 2016By Alex Keown, BioSpace.com Breaking News Staff BOSTON – An issue of patient compliance in taking Vertex (VRTX)’s new blockbuster cystic fibrosis drug Orkambi is at the […]
January 19, 2016By Mark Terry, BioSpace.com Breaking News Staff Ardley, N.Y.-based Acorda Therapeutics, Inc. (ACOR) announced today that it plans to acquire Turku, Finland-based Biotie Therapies Corp. (BITI) for […]
Drug developer Otonomy Inc said the U.S. Food and Drug Administration approved its treatment for an inflammatory ear disease. The company said the antibacterial drug, Otiprio, was being tested to […]
